50
Participants
Start Date
July 31, 2025
Primary Completion Date
January 13, 2028
Study Completion Date
January 13, 2028
Encorafenib + Binimetinib
Participants will have received a clinical decision to begin encorafenib plus binimetinib treatment as a second-line treatment for metastatic melanoma, in accordance with current Summary of Product Characteristics
NOT_YET_RECRUITING
Southend University Hospital, Westcliff-on-Sea
RECRUITING
Queen Elizabeth Hospital, Birmingham
RECRUITING
Addenbrookes Hospital, Cambridge
NOT_YET_RECRUITING
University Hospital Coventry and Warwickshire, Coventry
RECRUITING
Royal Marsden Hospital, London
RECRUITING
Royal Preston Hospital, Preston
RECRUITING
Southampton General Hospital, Southampton
Lead Sponsor
Vitaccess Ltd
INDUSTRY
Pierre Fabre Ltd
INDUSTRY